Medpace (NASDAQ:MEDP) CEO August Troendle Sells 14,747 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 14,747 shares of the firm’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $595.26, for a total transaction of $8,778,299.22. Following the completion of the sale, the chief executive officer owned 899,415 shares in the company, valued at $535,385,772.90. This represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Medpace Stock Up 0.8%

Shares of NASDAQ MEDP traded up $4.42 during trading hours on Tuesday, hitting $590.18. 219,107 shares of the stock were exchanged, compared to its average volume of 415,017. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $625.00. The firm has a fifty day moving average price of $541.26 and a 200-day moving average price of $426.46. The company has a market cap of $16.62 billion, a PE ratio of 41.27, a PEG ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same period last year, the firm earned $3.01 earnings per share. Medpace’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medpace

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quent Capital LLC acquired a new stake in Medpace during the third quarter worth about $25,000. Optiver Holding B.V. acquired a new position in shares of Medpace in the third quarter worth about $27,000. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group raised its holdings in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after purchasing an additional 71 shares during the period. Finally, Quarry LP acquired a new stake in Medpace in the 3rd quarter worth about $35,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on MEDP. Mizuho boosted their target price on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research note on Friday, October 24th. William Blair reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. Barclays lifted their price objective on shares of Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a research note on Friday, October 24th. BMO Capital Markets began coverage on shares of Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective on the stock. Finally, Jefferies Financial Group upped their target price on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research report on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $487.18.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.